Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Back
Association details:
Biomarker:
BRAF V600
Cancer:
Cutaneous Melanoma
Drug:
Keytruda (pembrolizumab)
(
PD1 inhibitor
) +
Mekinist (trametinib)
(
MEK inhibitor
)
Direction:
Sensitive
Evidence:
Evidence Level:
Sensitive: A2 - Guideline
Source:
NCCN
Published date:
02/19/2021
Excerpt:
Melanoma: Cutaneous...Metastatic or unresectable disease…Combination targeted therapy and immunotherapy if BRAF V600-activating mutation present…Dabrafenib/trametinib + pembrolizumab
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login